Sarcopenia refers to the age-related loss of skeletal muscle mass and strength. It leads to decreased physical performance, loss of independence, and poor quality of life in older adults. Treatment for sarcopenia involves regular exercise and resistance training along with healthy diet and nutrient supplementation. Pharmaceutical treatments options also include megestrol acetate, testosterone, and selective androgen receptor modulators.
The global sarcopenia treatment market is estimated to be valued at US$ 3.01 Bn in 2023 and is expected to exhibit a CAGR of 4.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
The sarcopenia treatment market is expected to witness high growth owing rising geriatric population globally. As per United Nations report, the number of people aged 65 years or over is projected to grow to nearly 1.5 billion in 2050 from 703 million in 2019. Growing aged population is increasing the risk of sarcopenia leading to greater adoption of treatment options such as nutrient and protein supplements, resistance training programs and testosterone therapy. The other driver for market growth is increasing awareness and diagnosis rates of sarcopenia. Several diagnostic guidelines and criteria developed by European Working Group on Sarcopenia in Older People (EWGSOP) and Foundation for the National Institutes of Health (FNIH) are helping in early detection and treatment of sarcopenia.
SWOT Analysis
Strength: Early diagnosis and appropriate treatment can help manage sarcopenia. Various drugs and therapies are available to treat loss of muscle mass and strength. Rising awareness about sarcopenia and available diagnostic and treatment options.
Weakness: Lack of standardized diagnostic criteria and biomarkers makes diagnosis challenging. High cost of approved therapies limits widespread adoption.
Opportunity: Growing geriatric population prone to sarcopenia presents large market potential. Novel diagnostic tools and drug candidates in pipeline can address unmet needs.
Threats: Patent expiries of blockbuster drugs will increase competition. Economic slowdown can reduce healthcare spends allocated for sarcopenia.
Key Takeaways
The global Sarcopenia Treatment Market Share is expected to witness high growth. With rising geriatric population globally, the prevalence of age-related muscle loss is steadily growing. This presents lucrative opportunities for players in this market.
Regional analysis
North America currently dominates the sarcopenia treatment market owing to rapidly growing senior population and higher adoption of expensive treatment options. However, Asia Pacific region is poised to witness fastest growth during the forecast period driven by large patient pool, changing lifestyles, and improving access to healthcare in countries like China and India.
Key players
Key players operating in the Sarcopenia Treatment market are Abbott Laboratories, Novartis AG, Eli Lilly and Company, Merck & Co., Inc., GlaxoSmithKline plc. Majority of the approved drugs are from large pharmaceutical companies. However, many new players are actively exploring novel therapeutic approaches to tap into the significant unmet needs.
Popular Posts
